Clinical Cancer Research Versailles No Abst Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhan, H. C.
Right arrow Articles by Tickoo, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhan, H. C.
Right arrow Articles by Tickoo, S. K.
Clinical Cancer Research Vol. 9, 4897-4905, October 15, 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Differential Expression of the Enzyme That Esterifies Retinol, Lecithin:Retinol Acyltransferase, in Subtypes of Human Renal Cancer and Normal Kidney

Hui Chun Zhan, Lorraine J. Gudas, Dean Bok, Robert Rando, David M. Nanus and Satish K. Tickoo1

Pharmacology Department [H. C. Z., L. J. G.], Departments of Medicine and Urology [D. M. N.], and Department of Pathology, Weill Medical College, Cornell University, New York, New York 10021 [S. K. T.]; Department of Neurobiology and Brain Research Institute, Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles, California 90095-7000 [D. B.]; and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115 [R. R.]

Purpose: Retinoids, a group of compounds, including vitamin A (retinol), and related metabolites, have been shown to regulate the growth and differentiation of many types of cells. IFN-{alpha} and either 13-cis-retinoic acid or liposomal all-trans retinoic acid have been used in the treatment of patients with metastatic renal cell carcinoma. We knew that samples from renal cell carcinomas contained greatly reduced levels of retinol and retinyl esters relative to samples from normal human kidney. This prompted us to examine the levels of LRAT (lecithin:retinol acyltransferase) protein in various subtypes of human kidney cancers relative to normal human kidney by immunohistochemistry.

Experimental Design: We examined 31 partial or radical nephrectomy specimens diagnosed with kidney tumors between 1997 and 1998. Representative paraffin-embedded tissue blocks from each tumor, with each containing adjacent nonneoplastic renal parenchyma, were used for immunohistochemical analysis with affinity purified antibodies to human LRAT protein.

Results: LRAT protein was detected at high levels in the epithelial cells in the tubules and the lining of Bowman’s capsule in the glomeruli of normal, nonneoplastic kidney sections. Among the 31 tumors, there were 13 cases of conventional (clear cell) renal cell carcinoma (RCC; including 2 multilocular cystic RCCs), 7 papillary RCC, 6 chromophobe RCC, 1 RCC, unclassified, and 4 renal oncocytoma. All tumors showed diffuse immunoreactivity for LRAT. In each case, the staining was uniform throughout the tumor, with only minimal variation in the staining intensity between different areas. All 4 renal oncocytomas, 2 of 6 chromophobe RCCs, 1 conventional (clear cell) carcinoma, 1 RCC, unclassified, and 2 conventional RCCs, which were of the multilocular cystic-type stained strongly (3+) for LRAT. In contrast, the remaining conventional RCCs and the papillary RCC samples stained much less intensely for LRAT. Of the 10 tumors that stained 3+ for LRAT in the study, 9 were either benign tumors or tumors with low malignant potential.

Conclusions: These data show that LRAT expression is higher in renal tumors with an indolent biological behavior. Additional studies will ascertain if LRAT possesses any prognostic or therapeutic role in renal cancer.




This article has been cited by other articles:


Home page
J. Cell Sci.Home page
I. Nazarenko, R. Schafer, and C. Sers
Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells
J. Cell Sci., April 15, 2007; 120(8): 1393 - 1404.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
T. Choueiri, B. Rini, J. Garcia, R. Baz, R. Abou-Jawde, S. Thakkar, P Elson, T. Mekhail, M Zhou, and R. Bukowski
Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma
Ann. Onc., February 1, 2007; 18(2): 249 - 255.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. E. Touma, J. S. Goldberg, P. Moench, X. Guo, S. K. Tickoo, L. J. Gudas, and D. M. Nanus
Retinoic Acid and the Histone Deacetylase Inhibitor Trichostatin A Inhibit the Proliferation of Human Renal Cell Carcinoma in a Xenograft Tumor Model
Clin. Cancer Res., May 1, 2005; 11(9): 3558 - 3566.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Boorjian, S. K. Tickoo, N. P. Mongan, H. Yu, D. Bok, R. R. Rando, D. M. Nanus, D. S. Scherr, and L. J. Gudas
Reduced Lecithin: Retinol Acyltransferase Expression Correlates with Increased Pathologic Tumor Stage in Bladder Cancer
Clin. Cancer Res., May 15, 2004; 10(10): 3429 - 3437.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.